Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
about
Linking form to function: Biophysical aspects of artificial antigen presenting cell designMesothelioma tumor cells modulate dendritic cell lipid content, phenotype and functionTherapeutic cancer vaccines and combination immunotherapies involving vaccinationSemi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumorDirect ex vivo analysis of dendritic cells in patients with hepatocellular carcinomaAlterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinomaExpression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1 alpha DCs induced in vivo by IFN-alpha in patients with chronic hepatitis BRegulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathwayDendritic cell defects in patients with cancer: mechanisms and significance.Spontaneous apoptosis of blood dendritic cells in patients with breast cancer.Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer.HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulationThe role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells.Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.Dendritic cell immunotherapy for breast cancer.Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancerArtificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.Breast cancer stem cells, pathways and therapeutic perspectives 2011.Breast cancer stem cells: implications for therapy of breast cancer.The anergic state in sarcoidosis is associated with diminished dendritic cell function.Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells.Poor prognosis osteosarcoma: new therapeutic approach.The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion ChemotherapyAltered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients.The Janus face of dendritic cells in cancer.Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients.Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine.Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
P2860
Q27002652-5058168B-CE8C-4473-8BCD-A69835F2E1EDQ28392070-F06470B1-5688-4BB6-8C56-7FB64BC92824Q28397609-E3365906-9ADF-47A2-A826-2C78980FCE20Q33728439-9DC3F80E-D850-42B7-9634-55EBD9E58643Q33868428-C06C2F7F-6F25-42DC-8687-303CF3BA074BQ33997905-F898478C-C6C2-494C-9984-8A5627F8B2A3Q34012742-4B6B5F16-6688-4A0E-89A4-D7C7A4FA02A8Q34314210-AB0C9199-EBFA-479B-8DBB-AF1EDD49DFC9Q34480672-4ABCDEF9-BE7C-4D12-A1E8-0F11830E2480Q34480685-6D433A6D-6655-4626-B0B4-5EC6603529E3Q34648541-818BF637-1F7D-4294-9F7C-0E1C9B499E94Q34768502-5946EFA3-0AE5-4A73-A0CE-FE3316EED808Q34768526-B471D40C-4F6C-488A-A903-C7782657A93BQ34982772-FFA07270-730F-4A70-9026-DE10F0BE406DQ34983989-B0185298-0296-40AC-9639-78AA6787D653Q35062106-C4403579-5939-4503-B6CB-DC4681AB981CQ35579455-238BD0F3-2B2E-4B5B-8D2C-D74956BCF178Q35584599-917B263A-5EB0-4A63-8BEC-13AE46860E85Q35793849-AA9075EA-96B1-492F-8360-F6B0CC4F3FB3Q36150417-B4B9F864-2C60-4B57-BF41-252D9D61E9B6Q36262281-3A94013B-B8F9-4E30-9E50-6E1ABF1226DDQ36383130-41A0A0D2-FB45-4C24-A50D-4B70CD7201F3Q36464882-6BBA5E57-7BEF-47C2-A5E7-959EFA6254E0Q36480998-E81CCB7D-0F9D-4C68-9AB6-34F084BF19F6Q36611476-B56CD745-B33B-4F01-A30E-BC2A0D2C8F17Q36625004-0E78F58F-91BC-47F6-982A-E994948C2BAAQ36821232-D45CA23A-09B9-41CE-8FE1-E9BC3DD9585DQ36946326-EAF3DDD7-7BB8-439F-B84D-529899053A2CQ36955061-82A3828B-CE48-43FD-8580-62FDDB04D375Q36995998-ACF54A00-8E35-4BE6-A664-F0153D23EC4CQ37121744-E3D59B8A-97E2-4FE6-ABD5-9A09045F2B19Q37188469-0A80877D-D73E-448D-88C0-744D2CAE6094Q37204018-F9BC04C3-3A3C-4FDD-93FA-C43E2622270CQ37257918-15074AD0-7971-47E3-83A6-4EE0FEE628BEQ37287170-D7534AB2-DBBF-419E-BCD3-CCE65A77276EQ37366273-C7746722-B60E-4A87-B9E2-A93349E28775Q37448957-088249DE-28CB-448D-8D56-22921E94BA32Q37513871-3CDD6DEF-7C5D-4CC2-911C-530BAEB7BEC0Q37686631-13B64E1C-3DC3-43B1-A347-8362D56F87CBQ37735454-05251F11-F432-4A61-9D5A-C864E4A66F4C
P2860
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@ast
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@en
type
label
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@ast
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@en
prefLabel
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@ast
Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
@en
P2093
P2860
P50
P356
P1476
Altered maturation of peripheral blood dendritic cells in patients with breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601243
P407
P577
2003-10-01T00:00:00Z